Table 2:
Outcomes in Patients with Greater than 60 Days Follow-Up Data (n=126)
| A | B | C | |||||
|---|---|---|---|---|---|---|---|
| Variable | EUS/ERCP Combined | % or (IQR) | EUS Then ERCP | % or (IQR) | ERCP, +/− EUS | % or (IQR) | EUS Combined (A) vs Sequential (B+C)) |
| p-value | |||||||
| Total | 60 | 22 | 44 | ||||
| Age Adjusted Charlson Comorbidity Index, Median | 3 | (0,2) | 2 | (0,2) | 3 | (0,2) | 0.793 |
| Inpatient Status, n (%) | 21 | 35 | 3 | 13.6 | 11 | 25 | 0.116 |
| Stage, n (%) | 0.429 | ||||||
| I/II | 27 | 45 | 10 | 45.5 | 23 | 52.3 | |
| III | 10 | 16.7 | 5 | 22.7 | 11 | 25 | |
| IV | 20 | 33.3 | 7 | 31.8 | 7 | 15.9 | |
| Length of Follow Up, Days, Mean (STDV) | 294.2 | (215.1) | 320 | (273) | 389.7 | (266.8) | 0.103 |
| PDAC Therapy | |||||||
| Chemotherapy | 53 | 88.3 | 20 | 90.9 | 39 | 88.6 | 0.229 |
| Surgery | 27 | 45 | 8 | 36.4 | 28 | 63.6 | 0.292 |
| Stent Failurea, n (%) | 20 | 33.3 | 5 | 22.7 | 11 | 25 | 0.307 |
| Repeat ERCP, n (%) | 18 | 30 | 4 | 18.2 | 11 | 25 | |
| Total Procedures for Adequate Biliary Drainage, Median | 1 | (1,2) | 1 | (1,2) | 1 | (1,2) | 0.220 |
| Post Procedure Total Inpatient days for Biliary Drainage and Diagnostic Sampling, Mean (STDV) b | 4.6 | (4.9) | 10 | (9.5) | 3.4 | (2.6) | 0.858 |
| Time to Initiation of PDAC Therapy, Mean (STDV)c | 25.2 | (15.6) | 50.6 | (100.7) | 38.5 | (38.3) | 0.046 |
a
Defined as failure for resolution of jaundice, new jaundice, cholangitis or stent occlusion on follow up after biliary stent placement.
b
Aggregate inpatients days attributable to procedures for diagnostic sampling and/or maintenance of biliary decompression following index procedure.
c
Time interval from index procedure to first therapy directed toward PDAC (chemotherapy or resection)